Loading organizations...
§ Private Profile · Nouzilly, Centre, France
Biotechnology company developing novel monoclonal antibody therapeutics for infertility treatments, focused on enhancing gonadotropin activity.
Igyxos Biotherapeutics, based in Nouzilly, France, develops novel monoclonal antibody-based therapeutics aimed at improving infertility treatments for men and women by enhancing gonadotropin activity, such as FSH, for better efficacy and fewer injections. The company pioneers the first mAb designed to bind to and potentiate reproductive hormones, addressing limitations in current infertility solutions. Igyxos has successfully raised Series A funding from investors including BPI France, Go Capital, and UI Investissement. Its leadership team includes CEO Florent Ferré, Chief Medical Officer Dr. Elke Bestel, and founder Marie-Christine Maurel, who also serves as Chief Scientific Officer. Spun out of ReproPharm in 2017, Igyxos was founded by Marie-Christine Maurel. Its business model centers on biotechnology company funded through venture capital, including Series A funding.
Igyxos has raised $8.5M across 1 funding round.
Igyxos has raised $8.5M in total across 1 funding round.
Igyxos has raised $8.5M across 1 funding round. Most recently, it raised $8.5M Series A in March 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 23, 2019 | $8.5M Series A | — | Benoit Barteau, GO Capital, Jean Briac Lesne | Announced |
Igyxos has raised $8.5M in total across 1 funding round.
Igyxos's investors include Benoit Barteau, Go Capital, Jean-Briac LESNE.